Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
A Phase 1/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients With Inflammatory Lung Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Medical Monitor
- Phone Number: 626-304-3400
- Email: ARORAGE@arrowheadpharma.com
Study Locations
-
-
Washington
-
Nedlands, Washington, Australia, 6009
- Research Site 1
-
-
-
-
-
Auckland, New Zealand, 1010
- Research Site 1
-
Auckland, New Zealand, 1051
- Research Site 2
-
Auckland, New Zealand, 622
- Research Site 3
-
-
-
-
-
Krakow, Poland, 31-455
- Research Site 2
-
Oświęcim, Poland, 32-600
- Research Site 3
-
-
-
-
-
Barcelona, Spain, 08017
- Research Site 1
-
-
-
-
Bangkok
-
Bangkok Noi, Bangkok, Thailand, 10700
- Research Site 1
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Normal pulmonary function tests at Screening (NHVs only)
- Confirmed diagnosis of asthma based on source verifiable medical record (asthma patients only)
- No abnormal finding of clinical relevance at Screening (other than asthma for asthma patients)
- Stable dose of asthma controller medications prior to Screening (asthma patients only)
- If on allergen-specific immunotherapy, participants must be on a stable maintenance dose
- Non-smoking
- Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. Males must not donate sperm during the study and for at least 12 weeks following the last dose of study drug
- Willing to provide written informed consent and to comply with study requirements
Exclusion Criteria:
- Acute lower respiratory infection or asthma exacerbation within 30 days prior to first dose
- Positive COVID-19 test during Screening window
- Use of immunosuppressive medication within 90 days prior to first dose
- Receipt of any intranasal vaccine within 30 days prior to first dose
- Use of systemic corticosteroid therapy within 90 days prior to first dose
- Clinically significant health concerns (other than asthma in asthma patients)
- Human Immunodeficiency virus (HIV) infection, seropositive for Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV)
- Uncontrolled hypertension
- Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
- Use of illicit drugs
- Use of an investigational agent or device within 30 days prior to first dose
Note: additional inclusion/exclusion criteria may apply per protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
(0.9% NaCl)
|
calculated volume to match active treatment by inhalation of nebulized solution
|
|
Experimental: ARO-RAGE
ARO-RAGE Inhalation
|
single or multiple doses of ARO-RAGE by inhalation of nebulized solution
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From first dose of study drug through the end of study (EOS; up to 113 days)
|
From first dose of study drug through the end of study (EOS; up to 113 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline Over Time in Forced Expiratory Volume (FEV1)
Time Frame: Baseline through EOS (up to 113 days) or until serum soluble receptor for advance glycation end products (sRAGE) is ≥ 70% of baseline value
|
Baseline through EOS (up to 113 days) or until serum soluble receptor for advance glycation end products (sRAGE) is ≥ 70% of baseline value
|
|
Change from Baseline Over Time in Forced Vital Capacity (FVC)
Time Frame: Baseline through EOS (up to 113 days) or until serum sRAGE is ≥ 70% of baseline value
|
Baseline through EOS (up to 113 days) or until serum sRAGE is ≥ 70% of baseline value
|
|
Change from Baseline Over Time in Diffusing Capacity for Carbon Monoxide (DLCO)
Time Frame: Baseline through EOS (up to 113 days) or until serum sRAGE is ≥ 70% of baseline value
|
Baseline through EOS (up to 113 days) or until serum sRAGE is ≥ 70% of baseline value
|
|
PK of ARO-RAGE: Recovery of Unchanged Drug in Urine Over 0 to 24 Hours (Amount Excreted; Ae)
Time Frame: Through 24 hours post-dose
|
Through 24 hours post-dose
|
|
PK of ARO-RAGE: Percentage of Administrated Drug Recovered in Urine Over 0 to 24 hours
Time Frame: Through 24 hours post-dose
|
Through 24 hours post-dose
|
|
PK of ARO-RAGE: Maximum Observed Plasma Concentration (Cmax)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Time to Maximum Observed Plasma Concentration (Tmax)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to 24 Hours (AUC0-24)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to the Last Quantifiable Plasma Concentration (AUClast)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Area Under the Plasma Concentration versus Time Curve From Zero to Infinity (AUCinf)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Terminal Elimination Half-Life (t1/2)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Apparent Systemic Clearance (CL/F)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Apparent Terminal-Phase Volume of Distribution (VZ/F)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
|
PK of ARO-RAGE: Renal Clearance (CLr)
Time Frame: single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
single dose phase: up to 48 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 29 for NHVs, and up to 24 hours post-dose for participants with asthma
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ARORAGE-1001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.